SG11201807912SA - Vaccine against rsv - Google Patents

Vaccine against rsv

Info

Publication number
SG11201807912SA
SG11201807912SA SG11201807912SA SG11201807912SA SG11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA
Authority
SG
Singapore
Prior art keywords
international
archimedesweg
leiden
rsv
pct
Prior art date
Application number
SG11201807912SA
Inventor
Johannes Langedijk
Janneke Verhagen
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11201807912SA publication Critical patent/SG11201807912SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 011101011101111101100 1111 DIM III International Bureau ... .... ..Yjd (10) International Publication Number ..... ...,/ (43) International Publication Date WO 2017/174564 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: A61K 39/12 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: PCT/EP2017/057957 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: 4 April 2017 (04.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: 16163807.7 5 April 2016 (05.04.2016) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: LANGEDIJK, Johannes, Petrus, Maria; Archimedesweg 4-6, 2333 CN Leiden (NL). VERHA- GEN, Janneke, M; Archimedesweg 4-6, 2333 CN Leiden SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (NL). — as to applicant's entitlement to apply for and be granted a — (74) Agents: MANTEN, Annemieke et al.; Archimedesweg 4- 6, 2333 CN Leiden (NL). patent (Rule 4.17(11)) — of inventorship (Rule 4.17(iv)) = (81) Designated States (unless otherwise indicated, for every Published: kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — with international search report (Art. 21(3)) = = = = = = = = = = = = 1-1 7r ,tD 1 1 in IN ,—, IN IN 1-1 (54) Title: VACCINE AGAINST RSV 0 ei (57) : The present invention relates to novel nucleic acid molecules encoding a pre- fusion RSV F protein or immunologic - en. ) ally active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The inven - '' ,... °. tion further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).
SG11201807912SA 2016-04-05 2017-04-04 Vaccine against rsv SG11201807912SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163807 2016-04-05
PCT/EP2017/057957 WO2017174564A1 (en) 2016-04-05 2017-04-04 Vaccine against rsv

Publications (1)

Publication Number Publication Date
SG11201807912SA true SG11201807912SA (en) 2018-10-30

Family

ID=55661317

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807912SA SG11201807912SA (en) 2016-04-05 2017-04-04 Vaccine against rsv

Country Status (18)

Country Link
US (3) US10729757B2 (en)
EP (1) EP3439694A1 (en)
JP (2) JP7233928B2 (en)
KR (3) KR102401247B1 (en)
CN (1) CN109069612A (en)
AU (1) AU2017248018A1 (en)
BR (1) BR112018070323A2 (en)
CA (1) CA3018139A1 (en)
CL (1) CL2018002825A1 (en)
EA (1) EA201892250A1 (en)
IL (1) IL262109B2 (en)
MA (1) MA43762A (en)
MX (1) MX2018012095A (en)
MY (1) MY193584A (en)
PE (1) PE20190433A1 (en)
PH (1) PH12018501912A1 (en)
SG (1) SG11201807912SA (en)
WO (1) WO2017174564A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361774B (en) * 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion rsv f polypeptides.
JP6840718B2 (en) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stabilized pre-soluble fusion RSV F polypeptide
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
MA47016A (en) 2015-10-22 2018-08-29 Modernatx Inc RESPIRATORY VIRUS VACCINES
BR112018070323A2 (en) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv rsv vaccine
AU2017248021B2 (en) * 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
EP3624844A1 (en) * 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3681533A1 (en) * 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
EP3746090A4 (en) * 2018-01-29 2021-11-17 ModernaTX, Inc. Rsv rna vaccines
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20220273787A1 (en) * 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3188170A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
CN112220921B (en) * 2020-08-25 2022-08-16 北京交通大学 Combined vaccine for respiratory syncytial virus infection
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN114277039B (en) * 2021-10-25 2024-06-21 浙江君怡生物科技有限公司 Respiratory syncytial virus mRNA vaccine and preparation method and application thereof
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535178T2 (en) 1994-06-10 2006-12-14 Genvec, Inc. ADENOVER VECTOR SYSTEMS AND CELL LINES
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ES2333425T5 (en) 1995-06-15 2012-08-28 Crucell Holland B.V. Packaging systems for human recombinant adenovirus intended for gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (en) 1996-07-16 1998-12-18 Transgene Sa PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
KR100503701B1 (en) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
BR9908015A (en) 1998-02-17 2001-04-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1816205B1 (en) 1999-05-17 2011-08-10 Crucell Holland B.V. Recombinant Adenovirus based on serotype 48 (Ad48).
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
AU4346101A (en) 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
NZ523036A (en) 2000-05-08 2004-04-30 Davisco Foods Internat Inc Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Composition for the preservation of viruses
US20030232018A1 (en) 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2310247T3 (en) 2002-04-25 2009-01-01 Crucell Holland B.V. STABLE ADENOVIRAL VECTORS AND PROPAGATION METHODS OF THE SAME.
SI1497438T1 (en) 2002-04-25 2010-03-31 Crucell Holland Bv Means and methods for the production of adenovirus vectors
ES2357366T3 (en) 2002-05-14 2011-04-25 MERCK SHARP & DOHME CORP. ADENOVIRUS PURIFICATION PROCEDURES.
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2553541C (en) 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
CN101155915B (en) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 Virus purification using ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
EP2099486A2 (en) * 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
AU2008340949A1 (en) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
EP2257809B1 (en) 2008-02-29 2012-02-08 Tibotec Pharmaceuticals Method for identifying inhibitors against viruses that use a class i fusion protein
ES2532015T3 (en) 2008-11-03 2015-03-23 Crucell Holland B.V. Method for the production of adenoviral vectors
EP3718566B1 (en) * 2008-12-09 2024-06-12 Novavax, Inc. Modified rsv f proteins and methods of their use
KR101763093B1 (en) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. Simian Adenovirus Nucleic Acid- and Amino Acid-Sequences, Vectors Containing Same, and Uses Thereof
MX2012000036A (en) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vaccine.
US9492531B2 (en) 2009-06-24 2016-11-15 Glaxosmithkline Biologicals Sa Recombinant RSV vaccines
DK3178490T3 (en) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F protein compositions and methods for their preparation
WO2011020079A1 (en) 2009-08-13 2011-02-17 Calmune Corporation Antibodies against human respiratory syncytial virus (rsv) and methods of use
CN102575233B (en) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 Process for adenovirus purification from high cell density cultures
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
CA3062786C (en) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
PT2707385T (en) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104379733B (en) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 Tool changes the recombinant adenovirus group of end
MY169352A (en) * 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
JP6210998B2 (en) * 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 Infectious disease prevention method by combined use of vector vaccine and live vaccine
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EA035846B1 (en) 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Human antibodies binding to rsv g protein
US10196438B2 (en) 2013-04-15 2019-02-05 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
MX361774B (en) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion rsv f polypeptides.
PE20160045A1 (en) * 2013-06-17 2016-02-18 Crucell Holland Bv SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION POLYPEPTIDES F
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
PL3046536T3 (en) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Improved adenovirus formulations
JP6664338B2 (en) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic combination
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JP6840718B2 (en) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stabilized pre-soluble fusion RSV F polypeptide
BR112018070323A2 (en) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv rsv vaccine
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
EP3880243A1 (en) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
MX2021012991A (en) 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Recombinant influenza antigens.
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
JP2023519740A (en) 2020-04-02 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Stabilized vaccine composition
CA3188170A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection

Also Published As

Publication number Publication date
IL262109B2 (en) 2023-04-01
MA43762A (en) 2021-04-21
US11338031B2 (en) 2022-05-24
BR112018070323A2 (en) 2019-01-29
US20190125854A1 (en) 2019-05-02
US11801297B2 (en) 2023-10-31
IL262109A (en) 2018-11-29
CN109069612A (en) 2018-12-21
KR102500970B1 (en) 2023-02-17
KR20180132761A (en) 2018-12-12
EP3439694A1 (en) 2019-02-13
JP7233928B2 (en) 2023-03-07
JP2023029889A (en) 2023-03-07
MY193584A (en) 2022-10-19
PH12018501912A1 (en) 2019-06-17
WO2017174564A1 (en) 2017-10-12
PE20190433A1 (en) 2019-03-21
US20220288186A1 (en) 2022-09-15
KR20220075436A (en) 2022-06-08
CA3018139A1 (en) 2017-10-12
KR102401247B1 (en) 2022-05-25
EA201892250A1 (en) 2019-03-29
CL2018002825A1 (en) 2018-11-16
AU2017248018A1 (en) 2018-09-27
JP2019510497A (en) 2019-04-18
KR102491447B1 (en) 2023-01-20
US10729757B2 (en) 2020-08-04
MX2018012095A (en) 2019-01-10
KR20220018618A (en) 2022-02-15
IL262109B (en) 2022-12-01
US20200360506A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
SG11201807912SA (en) Vaccine against rsv
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201909011PA (en) Niraparib compositions
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201805001UA (en) Method of treating influenza a
SG11201901351UA (en) A patient interface, system and method
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same